Tuesday, 30 June 2026 11:10 AM
Company Update
Veteran-founded MedTech pioneer aligns with non-profit to bridge the medical "Care Cliff" for stroke, SCI, MS, amputees, and individuals facing complex neurological conditions while expanding a fully IRB-approved clinical trial pipeline for advanced electroceutical neurorehabilitation.
TAMPA, FL / ACCESS Newswire / June 30, 2026 / Neuro20 Technologies Corp., an emerging leader in advanced electroceutical medicine, today announced a strategic partnership with The Walk Foundation to tackle the steep clinical validation and commercial accessibility barriers currently holding back breakthrough neurorehabilitation.
The collaboration introduces a tactical Patient Access Initiative. This program utilizes charitable funding and donor sponsorships to place FDA-cleared Neuro20 PRO Systems directly into the homes of waiting patients. This allows individuals to bypass bureaucratic insurance delays while Neuro20 secures the institutional capital required to unlock widespread commercial market access.
BRIDGING THE "CARE CLIFF" CRISIS
For individuals recovering from stroke, spinal cord injuries, MS, or amputations, standard clinical rehabilitation is rarely enough. When formal insurance-covered sessions end, patients are frequently discharged into a "care cliff" where physical decline is almost inevitable without intensive, ongoing therapy.
The Neuro20 PRO Home Care System solves this crisis by bringing prescribed, provider-directed neurorehabilitation directly into the patient's home, securing the continuous, long-term care required to maintain progress and prevent regression. Moving far beyond traditional, isolated muscle stimulation, the closed-loop platform uses an advanced Smart Suit to target up to 44 muscles simultaneously. By deploying patented Patterned Electrical Muscle Stimulation (PEMS), the system fires intricate muscle groups in exact, synchronized sequences to force the brain and peripheral muscles to communicate, effectively rewiring neural pathways.
A PARTNERSHIP BORN FROM PERSONAL RECOVERY
The partnership between the two organizations was born from direct personal experience with neurological adversity. The Walk Foundation was originally founded by Dr. George Maltezos, who lives with progressive Multiple Sclerosis and serves as Director of Science for Neuro20. When Dr. Maltezos's MS advanced to a stage where he was physically unable to manage daily operations, the foundation became dormant.
The mission was recently revived by Tony Doblin, a recent bilateral amputee whose primary rehabilitation goal was simply to walk independently on the beach near his home again. By integrating the Neuro20 PRO System into a highly disciplined therapy program, Doblin not only achieved his beach-walking goal but progressed rapidly enough to complete a full 5K race after just three months. After completing multiple subsequent races, Doblin stepped forward to take the reins of the dormant foundation, now serving as its Executive Director.
"The opposite of disability is not ability; the opposite of disability is opportunity," said Doblin. "We don't simply fund technology. We fund possibilities, first steps, and moments that can change a life forever."
EMPOWERING MOVEMENT. INSPIRING LIVES.
The Patient Access Initiative removes financial barriers to bring these same milestones to other individuals facing life-altering mobility challenges:
Stroke Recovery: A stroke survivor stood independently for the first time in 44 years.
Veteran Mobility: A veteran took his first unassisted steps after a decade of limited mobility.
Parkinson's Disease: Professional entertainer Philip Esposito achieved significant improvements in gait, balance, and stamina after four weeks of twice-weekly sessions.
Spinal Cord Injury: Patients like Christina D. are utilizing donated home systems to halt physical decline after formal insurance coverage expires.
Video Showcase: Real Patients. Real Results. Watch the science behind the Neuro20 PRO System and witness the life-changing mobility breakthroughs of patients using the full-body muscle stimulation suit.
DE-RISKED PIPELINE FOR INSTITUTIONAL INVESTORS
Because this platform represents an entirely new medical category with no direct equivalent on the market, widespread commercial insurance reimbursement hinges entirely on translating individual victories into large-scale, multi-center empirical data. Headquartered in Tampa Bay, Florida, Neuro20 has neutralized early regulatory risks by building an extensive clinical trial pipeline that is fully mapped out and IRB-approved across elite academic and medical networks.
The company is preparing to launch a targeted Spinal Cord Injury (SCI) study at the Brooks Rehabilitation Clinical Research Center in Jacksonville, Florida, engineered specifically to measure changes in gait kinematics, walking speed, muscle performance, and autonomic nervous system responses. Concurrently, Neuro20 is advancing a specialized clinical research pipeline focused on the amputee population with the International Institute of Orthotics and Prosthetics (IIOP).
These foundational studies serve as the commercial launchpad for a broader research and clinical collaboration pipeline that includes work with Johns Hopkins Rehabilitation Network, the University of Delaware, the University of California San Francisco (UCSF), Midwestern University Medical School, and Binghamton University. These collaborative efforts span neurological, neuromuscular, prosthetics and orthotics, blood-flow, exercise, and biomedical engineering research initiatives.
"We have built a comprehensive Electrical Neuromuscular Modulation system that stabilizes the entire neural framework by balancing the sympathetic and parasympathetic nervous systems," said Dennis "DJ" Schmitt, Founder and CEO of Neuro20 Technologies Corp. "Our multi-center research pipeline is fully designed and IRB-approved with premier institutions. We are actively seeking visionary, institutional investors to fund these clinical trials, scale our proprietary data repository, and capture a massive share of the neuro-rehabilitation market."
IMMEDIATE CALL TO ACTION FOR DONORS AND SPONSORS
Seven patients have already received Neuro20 PRO Systems through this partnership. The immediate goal is to fund the next waiting patients through corporate sponsorships and community partnerships.
Additionally, the foundation is actively seeking corporate sponsors for "The Summit of Human Potential," a planned 2027 Mount Kilimanjaro expedition. This historic event will bring together 10 amputee climbers and a team of assisting professionals to demonstrate resilience and human potential on a global stage.
Individuals and organizations interested in sponsoring patients, funding research, or exploring investment opportunities are encouraged to connect directly with the teams.
About The Walk Foundation
The Walk Foundation is a nonprofit organization dedicated to empowering movement and inspiring lives through advocacy, fundraising, awareness initiatives, and direct support programs that help individuals facing neurological and mobility challenges gain access to care, technology, and opportunity. For more information, visit www.togetherwewalk.org.
About Neuro20 Technologies Corp.
Neuro20 Technologies Corp. is a medical technology pioneer advancing neurological care through proprietary electroceutical solutions. Founded and managed by a U.S. Marine Corps veteran and his wife, the company delivers a first-in-class, closed-loop platform engineered for provider-directed clinical use and prescribed home-care rehabilitation. For more information, visit neuro20.com.
Media, Corporate Sponsorship, & Investor Contacts:
Clinical Research & Investor Relations: Dennis (DJ) Schmitt, CEO/Founder | [email protected]
Patient Placement & Sponsorship: Tony Doblin, Executive Director | [email protected]
Media Contact & Assets Inquiries: Jana Schmitt, COO/Founder | [email protected]
SOURCE: Neuro20 Technologies